Keros Therapeutics Inc. (KROS) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Per the Roarable RQD rating, KROS scores 66 out of 100 (letter grade C+), with the verdict "Roarable Hold — Upper Neutral / Watch for Breakout." Across the five pillars:

• Fundamental Cash Engine: 19 / 20. Per the RQD rating, this pillar reflects ROIC of 85% and an FCF yield of 0%. The high ROIC is the strongest signal in the rating, but the 0% FCF yield indicates that the return metric is not translating into free cash flow relative to market value at the current price.
• Whale 13F Flow: 6 / 20. Per the RQD rating, institutional accumulation and options positioning score low. Investors should interpret this as limited evidence of large-holder conviction in the source data.
• Insider Conviction: 13 / 20. Per the RQD rating, SEC Form 4 and Congressional PTR cluster flow score moderately. This is a neutral-to-modest signal.
• Macro Regime Fit: 12 / 20. Per the RQD rating, beta is 1.0 and sector sensitivity is noted. This indicates market-average sensitivity to broad moves.
• Forensic Balance Sheet: 16 / 20. Per the RQD rating, Altman Z is 4.31, Piotroski F is 8/9, and Debt/Equity is 0.5. This is the second-strongest pillar and suggests a sound balance sheet posture.

For a prospective investor, the rating points to a stock with strong return-on-capital and balance-sheet metrics but weak institutional flow and no free-cash-flow yield at the current price. The "Watch for Breakout" label suggests the rating does not yet see a decisive catalyst. The valuation tradeoff is that multiples are largely unavailable in the source data, so price relative to earnings cannot be assessed from these sources.

Keros Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry, per the company profile. Per the recent news wire, the company is associated with a Phase II rinvatercept trial in DMD and a milestone payment. Not available in source data: the specific products sold, customer base, and revenue model beyond these references.

Per the SEC financials, FY 2025 shows a turn to positive operating and net income following losses in FY 2023 and FY 2024. Per the market data, operating margin is 27.7%, net margin is 35.7%, gross margin is 0%, and ROIC is 85%. Per the RQD rating, the Altman Z-Score is 4.31 and the Piotroski F-Score is 8/9, with Debt/Equity at 0.5. Cash declined from $559.9M in FY 2024 to $287.4M in FY 2025 per the SEC financials.

• Positive/neutral headlines (YELLOW): Coverage references 2027 DMD data for rinvatercept, a "Hold" rating from sell-side brokerages, a milestone payment and Phase II rinvatercept DMD trial, a BlackRock stake reported with sole voting power over 1.58M shares, and real-time movement commentary.
• Risk watch (RED): A Simply Wall St headline notes the stock dropped to US$10.66 and questions whether insiders sold too early.
• Per the market data, the stock closed at 11.36, down 2.15%, on volume of 205125.
• The Butterfly Supply-Chain Graph reports no supply chain and no butterfly links or proprietary signals.

• What is the trajectory of cash and burn after FY 2025, given cash fell from $559.9M to $287.4M and FY 2025 FCF is $106.0M while FCF yield is 0%?
• What drove the FY 2025 revenue increase from $3.5M to $244.1M, and is it recurring?
• What are the P/E, EV/EBITDA, and EPS figures, which are absent from the source data?
• What are the specific terms and timing of the rinvatercept DMD trial and the 2027 data readout?
• What is the debt structure, since the debt field is N/A for all periods?